CRF announces late breaking trials to be presented at TCT 2009 in San Francisco
WHAT:
The Cardiovascular Research Foundation has announced the late breaking trials that will be presented at TCT (Transcatheter Cardiovascular Therapeutics) 2009, the largest global medical and scientific symposium dedicated to interventional cardiovascular medicine.
TCT 2009 will also feature a new session on Electronic Medical Records (EMR). Leading experts will discuss the latest developments in EMR and its relevance to health care reform.
WHEN:
The TCT Scientific Symposium will be held September 21-25, 2009.
Late-breaking clinical trials will be highlighted during press conferences scheduled for Wednesday, September 23, Thursday, September 24, and Friday, September 25.
WEDNESDAY, SEPTEMBER 23
SPIRIT IV: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
COMPARE: A Prospective Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
ISAR-DESIRE 2: A Prospective Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Sirolimus-Eluting Stent Restenosis
SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-up from a Prospective Randomized Trial of Paclitaxel-Eluting and Sirolimus-Eluting Stents
LEADERS: Two-Year Follow-up from a Prospective Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
FAME: Two-Year Follow-up from a Prospective Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
THURSDAY, SEPTEMBER 24
CURRENT-PCI OASIS 7: A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel
CHARISMA GENOMICS SUBSTUDY: Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
TRITON-TIMI 38 ECONOMIC SUBSTUDY: Cost-Effectiveness of Prasugrel vs. Clopidogrel from a Prospective Randomized Trial of Patients with ACS Undergoing PCI
PLATO INVASIVE: A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
PROSPECT: A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
FRIDAY, SEPTEMBER 25
SYMPLICITY I: One-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension
DEBATER: A Prospective Randomized Trial of Drug-Eluting vs. Bare-Metal Stents With or Without Abciximab in STEMI
HORIZONS AMI: Two-Year Follow-up from a Prospective Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare-Metal Stents in STEMI
BCIS-1: A Prospective Randomized Trial of Intra-Aortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
NORDIC-BALTIC BIFURCATION STUDY III: A Prospective Randomized Trial of Side Branch Dilatation Strategies in Patients with Coronary Bifurcation Lesions Undergoing Treatment with a Single Stent
FAUST: A Prospective Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
WHERE:
The Moscone Center
San Francisco, CA
HOW TO REGISTER:
Media may apply for registration by clicking on:
http://www.tctconference.com/press/press-registration/press-pre-registration.html
Details on required press credentials can be found at:
http://www.tctconference.com/press/press-policies.html
Source: Cardiovascular Research Foundation
